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Abstract 
Background: Determining the need for prostate biopsy is frequently difficult and more objective 
criteria are needed to predict the presence of high grade prostate cancer (PCa). To reduce the 
rate of unnecessary biopsies, we explored the potential of using biomarkers in urine and plasma to 
develop a scoring system to predict prostate biopsy results and the presence of high grade PCa.  
Methods: Urine and plasma specimens were collected from 319 patients recommended for 
prostate biopsies. We measured the gene expression levels of UAP1, PDLIM5, IMPDH2, HSPD1, 
PCA3, PSA, TMPRSS2, ERG, GAPDH, B2M, AR, and PTEN in plasma and urine. Patient age, serum 
prostate-specific antigen (sPSA) level, and biomarkers data were used to develop two independent 
algorithms, one for predicting the presence of PCa and the other for predicting high-grade PCa 
(Gleason score [GS] ≥7).  
Results: Using training and validation data sets, a model for predicting the outcome of PCa biopsy 
was developed with an area under receiver operating characteristic curve (AUROC) of 0.87. The 
positive and negative predictive values (PPV and NPV) were 87% and 63%, respectively. We then 
developed a second algorithm to identify patients with high-grade PCa (GS ≥7). This algorithm’s 
AUROC was 0.80, and had a PPV and NPV of 56% and 77%, respectively. Patients who demon-
strated concordant results using both algorithms showed a sensitivity of 84% and specificity of 93% 
for predicting high-grade aggressive PCa. Thus, the use of both algorithms resulted in a PPV of 90% 
and NPV of 89% for predicting high-grade PCa with toleration of some low-grade PCa (GS <7) 
being detected.  
Conclusions: This model of a biomarker panel with algorithmic interpretation can be used as a 
“liquid biopsy” to reduce the need for unnecessary tissue biopsies, and help to guide appropriate 
treatment decisions. 
Key words: RNA, Cell-free, Gleason, scoring, high-grade, algorithm. 
1. Introduction 
Prostate biopsy (Bx) is currently the standard of 
care for prostate cancer (PCa) diagnosis, oftentimes 
reflexed after the detection of an elevated serum 
prostate-specific antigen (sPSA). Unfortunately, 
prostate Bx is not without potential complications, 
which might consist of discomfort, pain, bleeding, as 
well as the associated and financial costs. Bleeding has 
been reported in 6-13% of patients undergoing pros-
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tate Bx, while 0.3-4% experience symptomatic infec-
tion [1]. Furthermore, some newly diagnosed prostate 
cancers are indolent while other may be more aggres-
sive with metastastic potential, with resultant risk of 
death [3]. A sPSA level ≥4.0 ng/ml is frequently used 
as a threshold warranting a biopsy evaluation [4]. 
Elevated sPSA level may reflect benign prostatic hy-
perplasia (BPH), inflammation, or malignancy. Some 
series suggest that for patients with sPSA >4 ng/ml, 
only 20-30% will be positive for cancer, resulting in 
approximately 75% of patients undergoing an unnec-
essary biopsy.  
Additional biomarkers detected in urine, in-
cluding PCa gene 3 (PCA3) [5] and TMPRSS2-ERG 
gene fusions [6], have been shown to improve PCa 
detection specificity, especially when tested after dig-
ital rectal examination (DRE) [7]. Currently, the most 
used prognostic predictor of PCa’s clinical course is 
Gleason score (GS) based on biopsy results [8]. Data 
suggests that interventional strategies are useful in 
improving patient outcomes if high-grade PCa (GS 
≥7) is diagnosed early [9]. In fact, it has been proposed 
that low-grade PCa (GS <7) should not be classified as 
cancer and that predicting its presence is unnecessary 
[10].  
We recently reported the ability to predict the 
presence of PCa and high-grade PCa using a combi-
nation of biomarkers detected in urine and peripheral 
blood plasma [10]. We have improved upon this ap-
proach by adding additional biomarkers. In the cur-
rent study of 319 patients we used the expression lev-
els of 10 different genes, as analyzed in the urine and 
peripheral blood plasma, to develop a model system 
to predict the prostate Bx results. Using machine 
learning techniques, we optimized the number of in-
put features and identified the most accurate scoring 
algorithm. The goal of developing this testing is to: 1) 
reduce the incidence of negative biopsies and, 2) to 
determine patients which are more likely to have 
high-grade PCa  
For this study, we used genes (UAP1, PDLIM5, 
IMPDH2, HSPD1) determined to be PCa specific 
based on array expression data [2] along with genes 
(PSA, PCA3, TMPRSS2, ERG, AR, PTEN) highly im-
plicated as PCa specific. Phosphatase and Tensin 
Homolog (PTEN) is a tumor suppressor that nega-
tively regulates the phosphatidylinositide 3-kinase 
(PI3K) signaling pathway which is upregulated in 
approximately 40% of PCa, making it the most fre-
quently deregulated tumor suppressor gene in PCa 
[11], [12], [13]. High-levels of Androgen Receptor 
(AR), a nuclear steroid receptor, expression correlate 
with increased proliferation of cancer cells. PCa tu-
mors that overexpress AR are more aggressive, and 
associated with recurrence and a shorter relapse time 
[14], [15]. Genomic profiling of PCa shows AR path-
way alterations in 56% of primary PCa and 100% of 
metastatic disease [16]. TMPRSS2-ERG rearrange-
ments have been reported in 40-70% of PCa [17] and 
the translocation leads to dysregulation of expression 
of both genes as well as to the expression of a fusion 
transcript [18]. The ERG gene alone has been impli-
cated in the development and progression of PCa [19], 
[20].  
2. Materials and Methods 
2.1 Study Design and Patients 
From four urology practices, we collected urine 
and blood samples of 319 patients presenting with a 
clinical decision to proceed to a prostate biopsy. His-
tologic examination of standardized 12-core biopsies 
for each patient was provided. GS was performed 
according to the new modified system based on the 
2005 consensus conference [21]. Table 1 shows the 
characteristics of the recruited patients. Patients 
needed to be newly diagnosed to participate in the 
study, and we excluded patients receiving any ther-
apy for BPH or PCa. Urine samples were collected 
without DRE and processed within 48 hours of col-
lection without the use of any preservative. To assure 
that urine samples were not influenced by Bx or other 
manipulation, we collected a second sample within 
6-12 months of the first sample from 30 patients who 
had no significant clinical change. The patients were 
followed up to a year of the time of obtaining samples. 
If prostatectomy was performed, pathology data of 
prostatectomy was collected. In addition, we studied 
the biomarker profile in the urine and plasma in an 
independent cohort of 20 patients who were 
post-prostatectomy and used this group as control. 
None of the patients in this group had evidence of 
metastatic cancer. All laboratory work was performed 
with the IRB-approved protocol (Western IRB).  
2.2 Urine and Plasma Processing 
The urine sample from each patient was concen-
trated and plasma was separated and RNA from 
plasma and urine was extracted as previously de-
scribed [10]. 
2.3 Quantitative Reverse Transcrip-
tion-Polymerase Chain Reaction 
Quantitative reverse transcription real time 
polymerase chain reaction (qRT-PCR) was performed 
as previously detailed [10]. The PTEN primers and 
probes were purchased as TaqMan Gene Expression 
Assays (Applied Biosystems). The primer probe set 
for the new biomarker AR was designed to 
encompass exons 6 and 7 and produced a PCR 
product of 91bp: 5’-GGAATTCCTGTGCATGAAAGC
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-3’ (forward); 5’-CATTCGAAGTTCATCAAAGAATT
-3’ (reverse); VIC-CTTCAGCATTATTCCAGT-GMGB
NFQ (probe).  
 
Table 1: Characteristics of patients included in the development 
of the diagnostic algorithms. 
 
*cTMN: clinical tumor-node-metastases, none of the patients had evidence of 
metastasis and lymph node were not evaluated. 
 
2.4 Statistical Analysis  
We compared multivariate regression models 
incorporating sPSA, age, and different biomarker 
combinations and determined their relevance based 
on the area under the receiver operating characteristic 
curve (AUROC). A single model was selected based 
on the fewest variables yielding the most favorable 
AUROC. Cross validation was performed using 
bootstrapping. To validate the selected model, we 
used an algorithm based on the training set, first using 
the testing sample set, then the training and testing 
sets in combination. An independent investigator 
performed the testing. We used the same approach 
and training set to predict, respectively, the patients 
with advanced GS PCa and presence of high-grade 
PCa (GS ≥7). There were 103 patients with GS ≥7 in 
the entire group. Of which 68 out of the 213 patients in 
the training set had GS ≥7. 
3. Results 
3.1 Patient Characteristics 
Table 1 lists the characteristics of the patients in 
this study. Biopsies showed that 110 patients (34%) 
had BPH and 209 patients (66%) had PCa. The median 
age was 68 years (range: 46-92) in the PCa group and 
65 years (range: 45-84) in the no-cancer group. The 
difference was borderline significant (P=0.054). As 
expected, the difference in PSA levels was signifi-
cantly higher (P<0.0001) in the PCa group (median 5.7 
ng/ml, range 0.54-283.2 ng/ml) as compared with 
no-cancer patients (median: 4.6 ng/ml, range: 0.5-14.1 
ng/ml). However, 49 of the 209 patients (23%) with 
PCa had sPSA ≤4 ng/ml. In the no-cancer group, 37 
patients (34%) had sPSA ≤4 ng/ml. Of the patients 
with cancer, 106 (51%) had GS 6, 57 (27%) had GS 7, 
and 46 (22%) had GS >7. There was no significant 
difference in race between the PCa and the no-cancer 
groups.  
3.2 Comparing biomarkers in plasma 
Biomarkers in plasma were measured using a 
standardized approach. RNA was extracted from 
equal amount of plasma and an equal amount of RNA 
solution was used in each RT/PCR reaction for all 
patients. Therefore, no normalization was used. We 
compared the levels of various markers between pa-
tients with and without cancer as well as the levels of 
these biomarkers to plasma samples collected from 20 
patients after prostatectomy due to PCa (Table 2). The 
mRNA levels of PTEN, AR, ERG, UAP1, and PDLIM5 
were significantly different in patients with PCa than 
post-prostatectomy patients (Wilcoxon Rank Sum 
test) (Table 2). Compared with post-prostatectomy 
samples, the no-cancer group had significantly dif-
ferent levels of PTEN, AR, PDLIM5, IMPDH2, and 
HSPD1 mRNA. In comparing the PCa group directly 
with the no-cancer group, AR, TMPRSS2, ERG, PSA, 
PDLIM5, and HSPD1 levels were significantly dif-
ferent (Table 2). PSA mRNA in the plasma was ex-
tremely low and barely detectable. The reason for this 
is not clear. In contrast, urine PSA mRNA was signif-
icantly more abundant (Table 2). 
 
 
Table 2: Comparing biomarker levels in plasma between patients 
with cancer, without cancer, and post-prostatectomy (P-value is 
shown; NS: Not Significant). 
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3.3. Comparing biomarkers in Urine 
We concentrated all urine samples into 1 ml of 
urine and extracted RNA from all samples in a 
standardized fashion. Urine mRNA levels were 
compared between various groups before and after 
normalization to GAPDH or B2M as housekeeping 
genes (Table 3). As expected, the urine showed sig-
nificant difference in the levels of PSA and PCA3 be-
fore and after prostatectomy for both cancer and 
no-cancer groups of patients, irrespective of normali-
zation to housekeeping genes. However, there was no 
significant difference between cancer and no-cancer 
groups, except after normalization to GAPDH, which 
showed a significant difference in PDLIM5, UAP1, 
PSA, and ERG between the cancer and no-cancer 
groups (Table 3). ERG only was significantly different 
between the cancer and no-cancer groups after nor-
malization to B2M (Table 3).  
3.4 Prediction of biopsy-based PCa diagnosis  
To develop a multivariable model for predicting 
Bx results, we divided patients into training and test-
ing sets. Approximately two thirds (213 of 319: 68%) 
of patients were used for the training set and the de-
velopment of the model for predicting PCa presence 
on the Bx. This set included 139 patients (65%) with 
PCa and 35% without cancer. We used the measured 
biomarkers in urine and plasma, along with sPSA and 
age in this group of patients, to screen for best bi-
omarker combinations to predict the PCa patients, 
utilizing the algorithms indicated in Section 2.4. Lo-
gistic regression appeared to provide the best model 
with the least number of variables. One model in-
cluded only 8 variables (Figure 1) and showed an area 
under the AUROC of 0.87. The biomarkers selected in 
this algorithm were ERG, AR, B2M, and GAPDH 
mRNA in plasma and PCA3, PTEN, and B2M mRNA 
from urine in addition to the sPSA. Using the testing 
set (N=106), this algorithm showed 79% sensitivity, 
69% specificity, 83% PPV, and 63% NPV (Table 4) for 
detecting PCa using a cut-off at 0.64. The testing set 
results were comparable to those of the training set. 
When all patients were considered, the PPV and NPV 
were 87% and 63%, respectively (Table 4).  
 
 
Figure 1: ROC Curve for predicting the presence of PCa using the 
training set only. 
 
 
However, the majority of the missed patients 
using this algorithm were GS <7. The sensitivity and 
specificity were 89% and 83%, respectively, if we ig-
nore missing low-grade PCa (Table 4). The PPV and 
NPV for detecting patients with PCa using this algo-
rithm were 87% and 85%, respectively.  
As noted in Section 2.1, we collected a second 
urine sample from 30 individuals. Measuring the 
biomarkers in the new samples, we then used these 
values in the algorithm and compared the overall 
classification. All 30 patients retained their original 
classification (5 positive and 25 negative).  
 
Table 3: Comparing biomarkers levels in urine between patients with cancer, without cancer, and post-prostatectomy before and after 
normalization to either B2M or GAPDH (P-value is shown; NS: Not Significant). 
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3.5 Prediction of biopsy-based high-grade PCa 
Considered by current standards to be similar to 
those with BPH, it is important to distinguish GS <7 
PCa patients from GS ≥7 patients. Therefore, we 
grouped GS <7 (3+4 or 4+3) patients with no-cancer 
patients and used the training set for developing an 
algorithm for predicting GS ≥7 PCa on the Bx. The 
training set included 73 patients (34%) with 
high-grade PCa. As found previously, the best algo-
rithm was logistic regression. The AUROC was 0.85 
when using 13 variables; to assure reproducibility of 
results and to avoid overfitting, we used a model with 
only 8 biomarkers (ERG mRNA as measured in 
plasma and PSA, PTEN, PCA3, PDLIM5, GAPDH, 
and B2M mRNA as measured in urine) at an AUROC 
of 0.80. The ERG in plasma most likely reflects the 
biological relevance of TMPRSS2:ERG translocation. 
The PDLIM5 gene encodes for a protein that is be-
lieved to function as a scaffold protein involved in 
facilitating the activities of kinases related to muscles. 
Association between PDLIM5 expression and PCa has 
been reported [2] A four-gene expression signature 
for PCa cells consists of UAP1, PDLIM5, IMPDH2, 
and HSPD1 [2] appears to be involved in cancer cell 
proliferation [14]. The PSA mRNA was used with 
PCA3 in this model, with normalization to GAPDH 
and B2M also necessary. In addition, this model in-
corporated sPSA and age. 
 
 
Figure 2: Correlation between the score obtained for the prediction of 
high-grade PCa and the GS. 
 
Using this model with the test samples, which 
included 37 patients (35%) with high-grade PCa, the 
specificity was 80% but sensitivity 41% for predicting 
high-grade PCa patients. The PPV and the NPV were 
52% and 71%, respectively. These were similar to 
those seen in the training set. When all patients were 
used for predicting high-grade PCa, the sensitivity 
and specificity were 50% and 81%, respec-
tively. Furthermore, there was significant 
difference in scoring using this algorithm 
between various Gleason grades (P < 0.0001) 
(Figure 2).  
3.6 Combined algorithms for predicting 
PCa  
Each of the above two algorithms is a 
trained to predict different biopsy results. The 
first predicts the presence of any PCa while 
the second predicts the presence of 
high-Gleason grade PCa, although there is 
partial overlap. Since conceptually the most 
important aspect is predicting high-grade 
PCa, the strongest prediction is achieved 
when both algorithms are either both positive 
or both negative. When patients were tested 
by both algorithms, 200 of the 319 patients 
(63%) had concordant results. Predicting pa-
tients with high-grade PCa was significantly 
more reliable when the results were con-
cordant, with both sensitivity and specificity 
of 77%. The PPV and NPV were 57% and 89% 
(Table 4), the sensitivity and specificity for 
predicting any cancer were 62% and 91%, and 
PPV and NPV 90% and 65%, respectively. 
However, most of these patients who were 
Table 4: Sensitivity, specificity, positive predictive value and negative pre-
dictive value of the various algorithms. 
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missed (low sensitivity) were GS <7. If these patients 
with GS <7 are accepted as negative, the sensitivity 
and specificity of the results were 84% and 93%, and 
PPV and NPV 90% and 89%, respectively (Table 4).  
3.7. Correlation with prostatectomy findings 
 At one year of follow up, prostatectomy data 
was available on 73 of the 319 patients. All 73 patients 
with prostatectomy data were classified as cancer 
patients based on the biopsy. Of these patients only 19 
patients had GS 6. Of these 7 patients were 
re-classified as GS 7 (3+4) on the prostatectomy. In-
terestingly, 3 of these 7 patients were classified by the 
algorithm as high-grade prostate cancer, 2 as 
low-grade cancer and 2 as no-cancer. The number of 
cases with a change in GS classification is too small 
and did not statistically change the overall conclusion 
of the algorithms.  
4. Discussion 
Clearly sPSA is not reliable due to poor specific-
ity. Though Bx remains the commonly used for eval-
uating the presence or absence of high-grade PCa, it is 
well established that biopsies, as compared with 
prostatectomy, have a tendency to underestimate the 
GS and even miss the presence of cancer.  
Urine has been shown to contain biomarkers 
useful for determining the presence of PCa. In addi-
tion, peripheral blood derived plasma and serum 
contain biomarkers reflecting abnormal or neoplastic 
processes in various parts of the body. As detailed in 
Section 2.4, we developed algorithms for predicting 
the presence of, first, PCa and, second, high-grade 
PCa. However, we restricted our endpoint at this time 
to Bx results and prediction of Bx results [22]. In our 
research we followed the recommendation estab-
lished by the REMARK group [23]. To assure power 
greater than 80%, especially in detecting patients with 
GS ≥7, we recruited more patients with cancer for our 
group. Furthermore, the patients were blindly divid-
ed into training and testing sets, simulating prospec-
tive studies.  
The algorithms that we developed for predicting 
the presence of PCa and high-grade PCa both used 
few biomarkers (see Sections 3.4 and 3.5). The first 
model showed good sensitivity (76%) and specificity 
(78%). The sensitivity in the second model was low 
(50%), but specificity was excellent (81%). The reason 
for the low sensitivity is not clear; however, it is pos-
sibly due to the reliance on the Bx results in the 
training set, which used the results to predict the GS. 
We expected that a significant number of cases with 
biomarkers in urine and plasma would be consistent 
with high-grade GS if prostatectomy was used, but 
through Bx these were determined to be low grade. 
This lead to more tolerance for biomarker abnormali-
ties as low-grade PCa. While our long-range plan is to 
use prostatectomy data and long-term follow up for 
definite classification, at this time we must rely on the 
Bx results.  
To improve the reporting, we combined the two 
algorithms and considered patients with concordant 
positive or negative results based on both algorithms. 
This group comprised 63% of total patients (200 of 
319). Interestingly, the sensitivity in this group of 
predicting GS ≥7 PCa was 77%, with 77% specificity, 
57% PPV, and 89% NPV. However, the PPV was at 
90% for predicting the presence of any PCa and NPV 
at 89% for predicting high-grade PCa. 
The remaining patients with discordant results 
(37%) can reliably predict the presence or absence of 
PCa, with 76% sensitivity, 78% specificity, 87% PPV, 
and 63% NPV. However, we cannot reliably predict 
the presence of high-grade PCa in this group.  
With long-term follow up and through the col-
lection of prostatectomy data, we would be able to 
improve our algorithm by reclassifying patients for 
training and thus develop a reliable system based on 
biomarkers in urine and plasma. Our non-invasive 
approach and testing can provide a significantly im-
proved system to determine whether to biopsy, assess 
the presence or absence of PCa, and evaluate the 
grade of this cancer in a majority of patients.  
5. Conclusions 
Using a panel of biomarkers in urine and plas-
ma, we have developed a non-invasive approach to 
predict prostate Bx results. This model, which is based 
on using laboratory biomarkers and patient age, can 
be used as a “liquid biopsy” to reduce the need for 
tissue biopsies. Further studies have incorporated this 
model to clinical models such as the Prostate Cancer 
Prevention Trial risk calculator, which may provide a 
clinically very robust and practical approach for PCa 
screening and active surveillance. 
Acknowledgments 
The authors thank Benjamin Sampson for edito-
rial help.  
Author contributions  
Wanlong Ma, Ferras Albitar,a Kevin Diep, and 
Maher Albitar were involved in generating the data 
and involved in data analysis. Wanlong Ma, Lars 
Lund, Herbert A. Fritsche, Neal Shore, and Maher 
Albitar developed the concept of the study and de-
sign. 
Lars Lund and Neal Shore provided samples and 
patient data.  
 Journal of Cancer 2016, Vol. 7 
 
http://www.jcancer.org 
303 
All authors were involved with and approved 
the manuscript. 
Competing Interests 
Wanlong Ma, Ferras Albitar, Kevin Diep, and 
Maher Albitar are employed by NeoGenomics Labor-
atories.  
Lars Lund, Herbert A. Fritsche and Neal Shore: 
no financial conflict to disclose. 
References 
[1]  Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugos-
son J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker 
H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, 
Lilja H, Vickers AJ, Thompson IM. Evaluating the Prostate Cancer Prevention 
Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy 
cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 
2014 Feb;32(1):185-191. 
[2]  Guyon, Isabelle, Herbert Fritsche, Paul Choppa, Li-Ying Yang, Stephen Barn-
hill. A Four-Gene Expression Signature for Prostate Cancer Cells Consisting of 
UAP1, PDLIM5, IMPDH2, and HSPD1. UroToday International Journal 2009; 
2(4): 3834-3844. 
[3]  Zietman A. Evidence-based medicine, conscience-based medicine, and the 
management of low-risk prostate cancer. J Clin Oncol 2009; 27(30): 4935-4936. 
[4]  Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer 
among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N 
Engl J Med 2004; 350:2239-2246. 
[5]  De Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 (PCA3), a very sensitive and 
specific marker to detect prostate tumors. Cancer Res 2002; 62:2695-2698. 
[6]  St John J, Powell K, Conley-Lacomb MK, et al. TMPRSS2-ERG fusion gene 
expression in prostate tumor cells and its clinical and biological significance in 
prostate cancer progression. J Cancer Sci Ther 2012; 4(4):94-101. 
[7]  Prensner JR, Rubin MA, Wei JT, et al. Beyond PSA: The next generation of 
prostate cancer biomarkers. Sci Transl Med 2012; 4:127rv3. 
[8]  Humphrey PA. Gleason grading and prognostic factors in carcinoma of the 
prostate. Med Pathol 2004; 17:292-306.  
[9]  Carter HB, Partin AW, Walsh PC, et al. Gleason Score 6 adenocarcinoma: 
should it be labeled as cancer? J Clin Oncol 2012; 30(35):4294-4296. 
[10]  Ma W, Diep K, Fritsche HA, et al. Diagnostic and prognostic scoring system 
for prostate cancer using urine and plasma biomarkers. Genet Test Mol Bi-
omarkers 2014; 18(3):156-63. 
[11]  De Velasco MA, Uemura H. Preclinical remodeling of human prostate cancer 
through the PTEN/AKT pathway. Adv Urol 2012; 2012:1-12. 
[12]  Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of 
PTEN/MMAC1 gene alteration sin multiple metastatic prostate cancer tissues. 
Cancer Res 1998; 58:204–9. 
[13]  Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate 
cancers shows that PTEN genomic deletion is associated with poor clinical 
outcome. Br J Cancer 2007; 97:678-85. 
[14]  Li Y, Gao Y, Xu Y, et al. si-RNA-Mediated Knockdown of PDLIM5 Suppresses 
Gastric Cancer Cell Proliferation in Vitro. Chem Biol Drug Des 2014; doi: 
10.1111/cbdd.12428. 
[15]  Donovan MJ, Osman I, Khan FM, et al. Androgen receptor expression is 
associated with prostate cancer-specific survival in castrate patients with 
metastatic disease. BJU Int 2010; 105(4):462-67. 
[16]  Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of 
human prostate cancer. Cancer Cell 2010; 18(1):11-22. 
[17]  Phin S, Moore MW, Cotter PD. Genomic rearrangements of PTEN in prostate 
cancer. Front Oncol. 2013; 3:240. 
[18]  Jhaver A, Reid A, Clark J, et al. Detection of TMPRSS2-ERG translocations in 
human prostate cancer by expression profiling using GeneChip Human Exon 
1.0 ST arrays. J Mol Diagnon 2008; 10(1): 50-7. 
[19]  Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an 
early even associated with ERG gene rearrangements in prostate cancer. BJU 
Int 2011; 107(3):477-85. 
[20]  Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associ-
ated with tumor progression and early PSA recurrence in ERG fusion-positive 
and fusion-negative prostate cancer. Am J Pathol 2012; 181(2):401-12. 
[21]  Epstein JI, Allsbrook WC Jr, Amin MB, et al. Update on the Gleason grading 
system for prostate cancer: Results of an international consensus conference of 
urologic pathologists. Adv Anat Pathol 2006; 13(1):57-9. 
[22]  Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, 
Singer EA, Epstein JI. Gleason score 6 adenocarcinoma: should it be labeled as 
cancer? J Clin Oncol. 2012; 30(35):4294-6.  
[23]  McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. RE-
porting recommendations for tumor MARKer prognostic studies (REMARK). 
Nature Clinical Practice Oncology 2005; 2(8): 416-422. 
